Business
ZYUS Life Sciences Announces Closing of Debt Financing
ZYUS Life Sciences Announces Closing of Debt Financing Canada NewsWire /NOT FOR DI...
About this update from Zyus Life Sciences Corporation
[{"type":"text","content":"\n\n\nZYUS Life Sciences Announces Closing of Debt Financing\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n\n\n\n\n\n\nCanada NewsWire\n\n\n/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/SASKATOON, SK, March 5, 2026 /CNW/ - ZYUS Life Sciences Corporation (the \"Company\") (TSXV: ZYUS), a clinical stage life sciences company focused on the development and commercialization of novel non-opioid pharmaceutical drug candidates for pain management, today announces that it has closed a debt financing on March 5, 2026 pursuant to which it issued an unsecured promissory note (the \"Unsecured Note\") in the principal amount of C$0.5 million to an arm's-length third-party lender.\n\n\n\n\n\n\n\nThe Unsecured Note bears interest at a rate of 12 percent per annum from the date of issuance, calculated on a simple basis, and matures on August 5, 2026. Interest on the Unsecured Note is payable at maturity. The Unsecured Note is not convertible to equity, and the Company may prepay this Unsecured Note, including accrued interest, at any time without penalty or premium.The Company intends to use proceeds from the debt financing for general working capital purposes.The Unsecured Note pursuant to the debt financing is subject to notice requirement under the rules of the TSX Venture Exchange.About ZYUS Life Sciences CorporationZYUS (TSXV: ZYUS) is a clinical stage life sciences company focused on the development and commercialization of novel non-opioid pharmaceutical drug candidates for pain management. Through rigorous scientific exploration and clinical research, ZYUS aims to secure intellectual property protection, safeguarding its innovative therapies and bolstering shareholder value. ZYUS' unwavering commitment extends to obtaining regulatory approval of non-opioid-based pharmaceutical solutions, in pursuit of transformational impact on patients' lives. For additional information, visit www.zyus.com or follow us on X @ZYUSCorp.Cautionary Note Regarding Forward-Looking StatementsThis news release contains statem...